Pharco, Presidio team up to develop hepatitis C treatment for Egypt

Pharmaceutical companies Pharco and Presidio have entered into an exclusive licensing agreement in which Presidio’s HCV NS5A inhibitor PPI-668 drug will be used in developing a treatment for hepatitis C (HCV) infections in Egypt.

“This licensing agreement provides Pharco with an opportunity to develop an effective, safe and affordable treatment for Egyptians with HCV infection,” Dr. Sherine Helmy, Pharco Pharmaceuticals' vice chairman and CEO, said. “We believe that PPI-668, in combination with other therapeutic agents, offers another potential path to treat and hopefully cure patients.”

Pharco Pharmaceuticals was founded by Dr. Hassan Abbas Helmy in 1987, while Presidio Pharmaceuticals is a San Francisco-based clinical-stage pharmaceutical company whose current focus is on creating HCV infection treatments.

“PPI-668 is a potent HCV NS5A inhibitor with a favorable pharmacokinetic profile that has shown high SVR rates in combination with other direct acting antiviral agents” Richard Colonno, Presidio’s chief scientific officer, said. “We look forward to our collaboration with Pharco to provide HCV patients with this highly active inhibitor.”

Clinical development, commercialization and funding of PPI-668 in Egypt will come from Pharco, while Presidio will receive milestone payments, as well as royalties based on product net sales in Egypt.

Organizations in this Story


Want to get notified whenever we write about PharmiWeb ?
Next time we write about PharmiWeb, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.